<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89129">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016352</url>
  </required_header>
  <id_info>
    <org_study_id>10 045 08</org_study_id>
    <secondary_id>2011-A01091-40</secondary_id>
    <nct_id>NCT02016352</nct_id>
  </id_info>
  <brief_title>Cerebrospinal Fluid Proteome in Hydrocephalus</brief_title>
  <acronym>PROLIPHYC</acronym>
  <official_title>Cerebrospinal Fluid Proteome in Hydrocephalus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROLIPHYC is a collaborative prospective study that aims at discovering deep cerebrospinal
      fluid (CSF) proteome with a new clinically-compatible proteomics strategy, in a cohort of
      100 patients suspected of neurodegenerative diseases and/or normal pressure hydrocephalus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CSF proteome is the real time protein content that may reveal useful biomarkers for
      diagnosis and therapeutic decision-making. But the low protein concentration in CSF and the
      low volumes typically obtained after lumbar puncture precludes the conventional use of
      proteomic analysis. We miniaturized the method to be compatible with low-volume samples by
      combination of nanoLC-MS/MS analysis and combinatorial peptide ligand library technology to
      reduce the dynamic range of protein concentration in CSF and unmask previously undetected
      proteins. We demonstrated that this deep proteomic analysis allows profiling the CSF
      proteome with a reasonable depth, in short analytical times and good accuracy. We settled a
      clinically-compatible proteomics strategy targeting the deep CSF proteome discovery.

      The PROLIPHYC study is a prospective study that aims at analysing CSF proteome with our new
      strategy in a cohort of patients suspected of normal pressure hydrocephalus and/or related
      neurodegenerative diseases. The PROLIPHYC project combines detailed clinical and
      neuropsychological evaluation, gait analysis, MRI brain imaging, lumbar CSF dynamics and
      deep proteome. We hypothesize in the PROLIPHYC study that a specific cluster of polypeptides
      can be associated with Alzheimer disease, vascular dementia and normal pressure
      hydrocephalus profiles. Validating this hypothesis might be a significant step towards a
      proteomic lexicon of aging brain, neurodegenerative diseases and dementia.

      Neurosciences department and Alzheimer disease centre from the Toulouse University Hospital
      are both involved in this project. The deep proteomic study is performed in Toulouse by the
      Institute of Pharmacology and Structural Biology with the academic support of the Institute
      of Mathematics of Toulouse.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>CSF proteome measure</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>CSF extraction (3 ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation between CSF proteome and gait analysis</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>compare results from CSF proteome and gait analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between CSF proteome and MRI brain imaging</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>compare results from CSF proteome and brain imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Normal Pressure Hydrocephalus</condition>
  <arm_group>
    <arm_group_label>patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSF is taken from patients with hydrocephalus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>witness</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CSF extraction from patients that do not suffer from hydrocephalus</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>patient CSF extraction with hydrocephalus</intervention_name>
    <description>CSF extraction</description>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>witness CSF extraction from patient not suffering from hydrocephalus</intervention_name>
    <description>CSF extraction from patient not suffering from hydrocephalus</description>
    <arm_group_label>witness</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gait problems, cognitive decline, urinary incontinence and enlarged ventricles on
             imaging

        Exclusion Criteria:

          -  Psychiatric disorders

          -  Lumbar punction contraindication

          -  RMI contraindication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric SCHMIDT, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ERIC SCHMIDT, MD PhD</last_name>
    <phone>33561779381</phone>
    <phone_ext>33</phone_ext>
    <email>schmidt.e@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CECILE GAUCHET, PhD</last_name>
    <phone>33561778496</phone>
    <phone_ext>33</phone_ext>
    <email>gauchet.c@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Gauchet, PhD</last_name>
      <phone>33561778496</phone>
      <phone_ext>33</phone_ext>
      <email>gauchet.c@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Eric Schmidt, MD PhD</last_name>
      <phone>33561779381</phone>
      <phone_ext>33</phone_ext>
      <email>schmidt.e@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Schmidt, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bech-Azeddine R, Høgh P, Juhler M, Gjerris F, Waldemar G. Idiopathic normal-pressure hydrocephalus: clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting. J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):157-61. Epub 2006 Sep 29.</citation>
    <PMID>17012342</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hydrocephalus</keyword>
  <keyword>proteomic</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrocephalus</mesh_term>
    <mesh_term>Hydrocephalus, Normal Pressure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
